Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma

Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/refractory MM (RRMM). We observed that cfDNA positivity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldschmidt, Johannes M., Yee, Andrew J., Vijaykumar, Tushara, Pinto Rengifo, Ricardo A., Frede, Julia, Anand, Praveen, Bianchi, Giada, Guo, Guangwu, Potdar, Sayalee, Seifer, Charles, Nair, Monica S., Kokkalis, Antonis, Kloeber, Jake A., Shapiro, Samantha, Budano, Lillian, Mann, Mason, Friedman, Robb, Lipe, Brea, Campagnaro, Erica, O’Donnell, Elizabeth K., Zhang, Cheng-Zhong, Laubach, Jacob P., Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C., Raje, Noopur S., Knoechel, Birgit, Lohr, Jens G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983453/
https://www.ncbi.nlm.nih.gov/pubmed/35027656
http://dx.doi.org/10.1038/s41375-021-01492-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983453/
https://www.ncbi.nlm.nih.gov/pubmed/35027656
http://dx.doi.org/10.1038/s41375-021-01492-y

Ejemplares similares